Clinical outcomes after inferior vena cava resection for malignant disease. A single center experience of 51 vena cava resections
European Journal of Surgical Oncology · 2024
DOI: 10.1016/j.ejso.2024.108253 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2024. Verfasst von Lucas De Crignis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre Léon Bérard, Department of Surgical Oncology, Lyon, F-69008, France. Electronic address: lucas.decrignis@hotmail.fr. Hauptthemen laut MEDLINE: Vena Cava, Inferior. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: For tumors involving inferior vena cava (IVC), surgery with complete resection remains the first line treatment. Management of IVC after resection, either ligation without reconstruction or primary reconstruction, is debated. Our study aimed to evaluate type of venous reconstruction, anticoagulation management and morbidity. METHODS: A French single center database of patients who underwent partial or total circumferencial resection of the IVC for malignant disease was analyzed. Inclusion criteria were any oncologic procedure for a retroperitoneal neoplasm requiring concomitant resection of the IVC with or without venous reconstruction with prosthesis. Exclusion criteria were surgery before year 2000. Data were descriptive and reverse Kaplan Meier was used for follow-up calculation. The endpoints were the rate of prosthetic reconstruction, the use of anticoagulation and the post-operative outcomes. RESULTS: Fifty - one patients were included with a median duration of follow-up of 54.8 months. The majority of patients were men (56.9%). Median age of the population was 44.1 years. Most of the patients underwent surgery for primary testicular cancer and for sarcoma. Complete IVC resections were performed in 46 (90,2%) patients, 32 having a concomitant prosthetic replacement. Eight patients underwent aortic resection in the same operative time. Postoperative morbidity was 33.3%. Post-operative anticoagulation was done in 24 patients. At 1 month, four patients developed thrombosis in the prosthesis. CONCLUSIONS: IVC resections are feasible and safe. Venous reconstruction and postoperative management were planned according to the preoperative imaging and intraoperative findings. We propose a decision-tree for peri-operative management and anticoagulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Léon Bérard, Department of Surgical Oncology, Lyon, F-69008, France. Electronic address: lucas.decrignis@hotmail.fr.
- Centre Léon Bérard, Department of Surgical Oncology, Lyon, F-69008, France.
- Jean Mermoz Hospital, Department of Vascular Medicine, Lyon, F-69008, France.
- Jean Mermoz Hospital, Department of Vascular Surgery, Lyon, F-69008, France.
- Centre Léon Bérard, Department of Surgical Oncology, Lyon, F-69008, France; Univ Lyon, Inserm, U1032 LabTau, F-69003, Lyon, France.
Zitieren
APA
De Crignis, L., Guesnon, M., Morin, A., Aleksic, I., Rivoire, M., Meeus, P., Dupré, A., & Peyrat, P. (2024). Clinical outcomes after inferior vena cava resection for malignant disease. A single center experience of 51 vena cava resections. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2024.108253
Vancouver
De Crignis L, Guesnon M, Morin A, Aleksic I, Rivoire M, Meeus P, et al. Clinical outcomes after inferior vena cava resection for malignant disease. A single center experience of 51 vena cava resections. European Journal of Surgical Oncology. 2024. doi:10.1016/j.ejso.2024.108253
BibTeX
@article{DeCrignis2024,
author = {De Crignis, Lucas and Guesnon, Mathias and Morin, Axel and Aleksic, Ivan and Rivoire, Michel and Meeus, Pierre and Dupré, Aurélien and Peyrat, Patrice},
title = {Clinical outcomes after inferior vena cava resection for malignant disease. A single center experience of 51 vena cava resections},
journal = {European Journal of Surgical Oncology},
year = {2024},
doi = {10.1016/j.ejso.2024.108253}
}
EUVIMED